These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 15047211)

  • 21. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication.
    Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Lee HP; Song YS
    Cancer Lett; 2006 Aug; 239(2):198-204. PubMed ID: 16168561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
    Ørbo A; Kaino T; Arnes M; Larsen K; Pettersen I; Moe B
    Acta Obstet Gynecol Scand; 2009; 88(11):1234-42. PubMed ID: 19900140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
    Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
    Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival.
    Giuffrè G; Arena F; Scarfì R; Simone A; Todaro P; Tuccari G
    Oncol Rep; 2006 Aug; 16(2):257-63. PubMed ID: 16820900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions].
    Ma XX; Zhang SL; Gao S; Lu JM; Dong F
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
    Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
    Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
    Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
    Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
    Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
    Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas.
    Segawa T; Sasagawa T; Saijoh K; Inoue M
    Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
    Biesterfeld S; Klüppel D; Koch R; Schneider S; Steinhagen G; Mihalcea AM; Schröder W
    J Pathol; 1998 May; 185(1):25-31. PubMed ID: 9713356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
    Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
    Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.